Compliance With LDL-Lowering Therapy (Study P05467)(COMPLETED)

NCT ID: NCT00723723

Last Updated: 2022-02-16

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 555 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2008-01-31
• Study Completion Date: 2009-06-30

Brief Summary

This observational study is being conducted in patients receiving statin treatment as secondary prevention of coronary heart disease under the current standard of care in compliance with European guidelines. The purpose of the study is to evaluate the percentage of these patients that reach target LDL levels. Additionally this study will measure the patient's compliance to treatment as assessed by counting the returned tablets. Both assessments will be made at visits conducted 6-8 weeks after the first visit and 28-32 weeks after the first visit.

Conditions

Coronary Heart Disease; Hypercholesterolemia; Hyperlipidemia

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Patients with coronary heart disease

Patients being treated with a statin for secondary prevention of coronary heart disease

Statin

Intervention Type: DRUG

Statin

Interventions

Statin

Statin

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• willingness to participate in the study
• 18 years of age or more
• clinically established cardiovascular disease to be considered as patients in secondary prevention
• prior therapy with any statin without achieving goal (2.5 mmol/L of LDL cholesterol) at last lipid check performed

Exclusion Criteria

• None

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Merck Sharp & Dohme LLC

INDUSTRY

Sponsor Role: collaborator

Organon and Co

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

P05467

Identifier Type: -

Identifier Source: org_study_id